|
Summary Information: Nymox Pharmaceutical Corporation Common Stock (Bahamas) NASDAQ:NYMX |
  admin@troach.net |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company's lead drug candidate for benign prostatic hyperplasia (BPH) Fexapotide Triflutate (FT) has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be filing for approval in major economies around the world, including the United States and Europe.
__The following are links to various summary and news pages for __Nymox Pharmaceutical Corporation Common Stock (Bahamas) [ NYMX ]. __Note: Some Links might not have information for the company. |
|